Skip to main content
Septerna, Inc. logo

Septerna, Inc. — Investor Relations & Filings

Ticker · SEPN US Professional, scientific and technical activities
Filings indexed 117 across all filing types
Latest filing 2024-11-20 Interim / Quarterly Rep…
Country US United States of America
Listing US SEPN

About Septerna, Inc.

https://septerna.com/

Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs). The company leverages its proprietary Native Complex Platform™ to isolate and analyze GPCRs in their natural state, which facilitates the development of new therapies. Septerna is advancing a wholly-owned pipeline with an initial focus on endocrinology, immunology, inflammation, and metabolic diseases. One of its clinical programs involves SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator being evaluated for the treatment of mast cell-driven diseases.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2024
2024-11-20 English
8-K
Regulatory Filings
2024-11-20 English
SC 13D
Major Shareholding Notification
2024-11-04 English
SC 13G
Major Shareholding Notification
2024-11-04 English
SCHEDULE 13G
Major Shareholding Notification
2024-11-01 English
Director's Dealing 2024
Director's Dealing
2024-10-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.